grant
Optimizing prognostic and predictive algorithms using residual disease (RD) genomic biomarkers in HER2+ and TNBC
Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 1 Jun 2019Deadline 31 May 2030
NIHUS FederalResearch GrantFY20257S Gamma GlobulinAdjuvantAdjuvant StudyAdjuvant TherapyAdjuvant TrialsAffectAfter CareAfter-TreatmentAftercareAntibody-drug conjugatesAssayB blood cellsB cellB cellsB-Cell ActivationB-CellsB-LymphocytesB-cellBioassayBiological AssayBiological MarkersBiologyBreast CancerCALGBCancer and Leukemia Group BCell BodyCell CommunicationCell InteractionCell-to-Cell InteractionCellsCellular biologyCheckpoint inhibitorClinicalClinical TrialsCollaborationsCombination Drug TherapyComputer ModelsComputerized ModelsDataDetectable Residual DiseaseDisease-Free SurvivalDrug CostsDrug TargetingDrugsERBB2ERBB2 geneElasticityElementsEvent-Free SurvivalExpression SignatureGene ExpressionGene Expression ProfileGenesGenomicsHER -2HER-2HER2HER2 GenesHER2/neuHeterogeneityIgGImmuneImmune Cell ActivationImmune checkpoint inhibitorImmune mediated therapyImmunesImmunoactivatorsImmunoadjuvantsImmunoglobulin GImmunologic AdjuvantsImmunologically Directed TherapyImmunopotentiatorsImmunostimulantsImmunotherapyIn complete remissionInduction TherapyMalignant Breast NeoplasmMeasuresMedicationMinimal Residual DiseaseModelingNEOADJNEU OncogeneNEU proteinNatureNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNon-Polyadenylated RNANon-metastaticNonmetastaticOncogene ErbB2Operative ProceduresOperative Surgical ProceduresOutcomePathologicPatientsPharmaceutical PreparationsPlayPolychemotherapyPostoperativePostoperative PeriodPrediction of Response to TherapyPrognosisRNARNA Gene ProductsRNA SeqRNA sequencingRNAseqRelapseResearch SpecimenResidual NeoplasmResidual TumorsRibonucleic AcidRoleSYS-TXSpatial DistributionSpecimenSurgicalSurgical InterventionsSurgical ProcedureSystemic TherapyT-CellsT-LymphocyteTKR1TM-MKRTNBCTestingTreatment FactorTumor BiologyTumor CellTumor MarkersWomanactivated B cellsadjuvant protocoladjuvant treatmentaggressive breast cancerbio-markersbiologic markerbiomarkerc-erbB-2c-erbB-2 Genesc-erbB-2 Proto-Oncogenescancer sub-typescancer subtypescell biologychemotherapycohortcombination chemotherapycombination pharmacotherapycomplete responsecomputational modelingcomputational modelscomputer based modelscomputerized modelingcustomized therapycustomized treatmentdisease prognosticdrug/agenterbB-2 Genesgene expression patterngene expression signaturegenomic biomarkergenomic markerherstatinimmune activationimmune check point inhibitorimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunological statusimprovedimproved outcomeindividualized medicineindividualized patient treatmentindividualized therapeutic strategyindividualized therapyindividualized treatmentinduction therapiesmalignant breast tumormortalityneoplastic cellneu Genespatient specific therapiespatient specific treatmentpost treatmentpredict therapeutic responsepredict therapy responseprediction algorithmprognosis modelprognosticprognostic algorithmprognostic modelprognosticationresidual diseaseresponseresponse to therapyresponse to treatmentsocial rolespatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial relationshipspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicssupervised learningsupervised machine learningsurgerysurvival outcometailored medical treatmenttailored therapytailored treatmenttargeted agenttherapeutic responsetherapy predictiontherapy responsethymus derived lymphocytetranscriptional profiletranscriptional signaturetranscriptome sequencingtranscriptomic sequencingtreatment predictiontreatment responsetreatment response predictiontreatment responsivenesstriple-negative breast cancertriple-negative invasive breast carcinomatumortumor biomarkertumor specific biomarkerunique treatment
Description preview
Abstract
HER2-positive (HER2+) and triple negative breast cancer (TNBC) are the most aggressive clinical breast
cancer subtypes and share similar treatment approaches and unmet needs. Both are treated with either anti-
HER2 drugs (for HER2+), or immunotherapy (for TNBC), added to polychemotherapy prior to surgery, called
“neoadjuvant” therapy.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click